Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Omollo, Raymond ^a   Alexander, Neal ^b   Edwards, Tansy ^b   Khalil, Eltahir A G ^c   Younis, Brima M ^c   Abuzaid, Abuzaid A ^c   Wasunna, Monique ^a   Njoroge, Njenga ^a   Kinoti, Dedan ^a   Kirigi, George ^a   Dorlo, Thomas P C ^d,e   Ellis, Sally ^f   Balasegaram, Manica ^f   Musa, Ahmed M ^c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF KHARTOUM   (Sudan)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

^f DNDi   (Switzerland)

Author keywords

AmBisome ; Miltefosine; Protocol; RCT; Tri angular test; Visceral Leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE; STIBOGLUCONATE SODIUM; AMPHOTERICIN B; ANTIMONY GLUCONATE; ANTITRYPANOSOMAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

AFRICA; ARTICLE; ASPIRATION; BONE MARROW; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LYMPH NODE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SEQUENTIAL ANALYSIS; SINGLE DRUG DOSE; SPLEEN; VISCERAL LEISHMANIASIS; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; KENYA; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SUDAN; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIMONY SODIUM GLUCONATE; CHILD; DRUG THERAPY, COMBINATION; HUMANS; KENYA; LEISHMANIASIS, VISCERAL; MIDDLE AGED; PHOSPHORYLCHOLINE; RESEARCH DESIGN; SUDAN; TIME FACTORS; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; YOUNG ADULT;

EID: 79959679843     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-166     Document Type: Article

References (25)

1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996, 14(5):417-423. 10.1016/0738-081X(96)00057-0, 8889319.
2. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003, 3(2):87-98. 10.1016/S1473-3099(03)00517-6, 12560194.
3. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010, 4(10):e709. 10.1371/journal.pntd.0000709, 2964287, 21049059.
4. Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 2010, 4(10):e855. 10.1371/journal.pntd.0000855, 2964291, 21049063.
5. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010, 10(3):184-194. 10.1016/S1473-3099(10)70011-6, 20185097.
6. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006, 43(3):357-364. 10.1086/505217, 16804852.
7. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007, 196(4):591-598. 10.1086/519690, 17624846.
8. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002, 347(22):1739-1746. 10.1056/NEJMoa021556, 12456849.
9. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011, 377(9764):477-486. 10.1016/S0140-6736(10)62050-8, 21255828.
10. Ranque S, Badiaga S, Delmont J, Brouqui P. Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections. Malar J 2002, 1:13. 10.1186/1475-2875-1-13, 149384, 12473182.
11. Bellissant E, Benichou J, Chastang C. Application of the triangular test to phase II cancer clinical trials. Stat Med 1990, 9(8):907-917. 10.1002/sim.4780090807, 2218193.
12. Whitehead J. The Design and Analysis of Sequential Clinical Trials. 1983, Chichester: Ellis Horwood, 1.
13. Team RDC R: A Language and Environment for Statistical Computing. 2011, Vienna, Austria: R Foundation for Statistical Computing, Team RDC., http://www.R-project.org/
14. StataCorp LP College Station Texas 77845 USA Stata: Data Analysis and Statistical Software. 1996, StataCorp LP College Station Texas 77845 USA., http://www.stata.com
15. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. 2001, Oxford: Blackwell Scientific Publications, 4.
16. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008, 52(8):2855-2860. 10.1128/AAC.00014-08, 2493105, 18519729.
17. Dorlo TP, Hillebrand MJ, Rosing H, Eggelte TA, de Vries PJ, Beijnen JH. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 865(1-2):55-62. 10.1016/j.jchromb.2008.02.005, 18325856.
18. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's Guides (1989-2009). Icon Development Solutions 2009, Ellicott City, MD, USA.
19. de Vries PJ, van der Meide WF, Godfried MH, Schallig HD, Dinant HJ, Faber WR. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. Trans R Soc Trop Med Hyg 2006, 100(12):1183-1186. 10.1016/j.trstmh.2006.01.002, 16678871.
20. van der Meide W, Guerra J, Schoone G, Farenhorst M, Coelho L, Faber W, Peekel I, Schallig H. Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J Clin Microbiol 2008, 46(1):73-78. 10.1128/JCM.01416-07, 2224296, 17959763.
21. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). , http://www.ich.org/
22. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. , http://www.wma.net/en/30publications/10policies/b3/17c.pdf
23. Akaza Research Massachusetts USA OpenClinica: Open Source Clinical Trials Software. 2003, Akaza Research Massachusetts USA., http://www.openclinica.org
24. WHO-TDR Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards. 2005, WHO-TDR, WHO-TDR., http://apps.who.int/tdr/svc/publications/tdr-research-publications/operational-guidelines
25. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008, 47(8):1000-1006. 10.1086/591972, 18781879.